Alder BioPharmaceuticals Reports Second Quarter 2016 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Alder Biopharm (ALDR) Bullish View Reiterated at Brean Following Q2 Result and Recent Positive ALD403 Data
July 27, 2016 10:36 AM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and $45 price target on Alder Biopharm (NASDAQ: ALDR) following Q2 results, recent data showing ALD403's durability and Phase 3 data in the 1st-half of 2017.
Aschoff commented, "Alder ended 2Q16 with cash of $450M, which should be able to support operations into 2H18. On Monday, Alder announced positive top-line 24-week data demonstrating sustained migraine... More
Alder Biopharm (ALDR) PT Bumped to $62 at Jefferies as 403 Continues To Advance
July 27, 2016 8:29 AM EDTJefferies analyst Brian Abrahams reiterated a Buy rating and bumped his price target on Alder Biopharm (NASDAQ: ALDR) to $62.00 (from $61.00) as '403 continues to advance.
Abrahams commented, "ALD403 continues to advance on track, and expenses were in line with expectations. Announced... More
Alder BioPharma (ALDR) Misses Q2 EPS by 4c
July 26, 2016 4:17 PM EDTAlder BioPharma (NASDAQ: ALDR) reported Q2 EPS of ($0.79), $0.04 worse than the analyst estimate of ($0.75).
For earnings history and earnings-related data on Alder BioPharma (ALDR) click here.
... More